Article summary
This randomised, double-blind, placebo-controlled single ascending dose Phase I trial (n=40) assessed modified-release psilocybin (0.5 to 2 mg) in healthy adults with normal weight or overweight/obesity. The formulation produced predictable, prolonged psilocin exposure with similar pharmacokinetics across weight groups, and no serious or notable treatment-related safety concerns or measurable psychoactive effects were observed.
Continue to the original publication for the complete article.